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Abstract 
Purpose: Urinary angiotensinogen has been reported as a marker for the activation of 
intrarenal renin-angiotensin system (RAS) in various kidney diseases. To investigate the 
importance of urinary angiotensinogen in diabetic nephropathy, we compared the 
urinary levels of angiotensinogen, albumin and α1-microglobulin. 
Patients and methods: Japanese patients with type 2 diabetes at various stages of 
nephropathy (n=85) were enrolled and we measured albumin creatinine ratio (ACR) and 
urinary excretion of angiotensinogen and α1-microglobulin. We also compared the 
clinical data of the patients treated with or without angiotensin II receptor blockers 
(ARB) or angiotensin converting enzyme inhibitors (ACEI) (RAS inhibitors (+), n=51; 
RAS inhibitors (-), n=34). 
Results: Urinary angiotensinogen levels positively correlated with ACR (r=0.367, 
p=3.48x10-4) and urinary α1-microglobulin (r=0.734, p=1.32x10-15), while they 
negatively correlated with estimated glomerular filtration ratio (eGFR) (r=-0.350, 
p=1.02x10-5) and high density lipoprotein cholesterol (HDL-C) (r=-0.216, p=0.049). 
Multiple regression analysis was carried out to predict urinary angiotensinogen levels by 
employing eGFR, ACR and urinary α1-microglobulin as independent variables and only 
urinary α1-microglobulin entered the regression equation at a significant level. Although 
ACR was higher in RAS inhibitors (+) group, urinary α1-microglobulin and 
angiotensinogen did not show significant increase in RAS inhibitors (+) group. 
Conclusion: Urinary angiotensinogen well-correlated with urinary α1-microglobulin and 
reflected the tubular injuries which may be associated with the intrarenal RAS activation 
in the patients with type 2 diabetes. 
Key words: diabetic nephropathy, urinary biomarkers, renin-angiotensin system (RAS), 
angiotensinogen, α1-microglobulin, albumin 
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Introduction 
The role of local renin-angiotensin system (RAS) in kidney tissues in the 
pathophysiology of diabetic nephropathy has been emphasized1. The hyporeninemic 
hypoaldosteronism observed along with the progression of diabetic nephropathy and 
the efficacy of RAS inhibitors reducing the albuminuria in such patients also supported 
the notion that intrarenal RAS plays an important role in the progression of diabetic 
nephropathy. Sawaguchi et al reported that the baseline urinary excretion of 
angiotensinogen (10-150 μg/gCr) positively correlated with albumin creatinine ratio 
(r=0.77, p<0.001) and urinary β2-microglobulin (r=0.72, p<0.001) in type 2 diabetes 
patients with normo- and microalbuminuria. Furthermore, urinary angiotensinogen 
significantly correlated with annual decline of estimated glomerular filtration rate (eGFR) 
(r=-0.51, p<0.001) and higher level of urinary angiotensinogen is a risk for the 
progression of diabetic nephropathy2. Most of the clinical studies measuring urinary 
angiotensinogen and albumin levels demonstrated the strong correlation between two 
proteins with comparable molecular weight (67 and 65 kDa). Thus, it is still unknown 
whether urinary angiotensinogen is a marker of impairment of glomerular permeability 
like ACR, a marker of tubular interstitial injuries or a biomarker for the activation of 
intrarenal RAS in diabetic nephropathy. In current study, we measured ACR, urinary 
α1-microglobulin and urinary angiotensinogen levels in the patients with various stages 
of diabetic nephropathy and investigated the clinical significance of urinary 
angiotensinogen in diabetic nephropathy. 
 
Materials and Methods 
Patients 
We recruited Japanese patients with type 2 diabetes (n=85, 62.9 ± 11.3 years) into this 
study at Okayama University Hospital. The current study is sub-study of the report and 
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shared the recruited patients3. They were treated with oral hypoglycemic agents (n=48) 
and insulin treatment (n=49). The patients with hypertension (n=59) were treated with 
angiotensin II receptor blockers (ARB; n=49), angiotensin converting enzyme inhibitors 
(ACEI; n=13), calcium channel blockers (n=34) and diuretics (n=11). We compared the 
clinical data of the patients treated with ARB or ACEI (RAS inhibitors (+); n=51) without 
ARB and ACEI (RAS inhibitors (-); n=34). Dyslipidemia was noted in 53 patients and 
most of them were treated with statins (n=45). The patients with eGFR < 15 ml/min/1.73 
m2 or under dialysis were excluded from the current study. All recruited patients with 
type 2 diabetes agreed to measure urinary levels of α1-microglobulin and 
angiotensinogen. The study was conducted in accordance with the ethical principle of 
the Declaration of Helsinki and approved by ethical committee of Okayama University 
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences. We obtained 
written informed consent from each patient. 
 
Blood sampling and assays  
We measured overnight fasting serum levels of total cholesterol and low density 
lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, triglycerides (L 
Type Wako Triglyceride・H, Wako Chemical, Osaka, Japan), uric acid, creatinine (Cr), 
and urea nitrogen (UN). HbA1c levels were also measured. Urinary albumin was 
measured in random spot urine samples by standard immuno-nephelometric assay. The 
urinary albumin-creatinine ratio (ACR) was calculated. Estimated glomerular filtration 
rate (eGFR) was calculated by equation; eGFR (ml/min/1.73 m2)=194×Cr-1.094×age-0.287 
in male and eGFR (ml/min/1.73 m2)=194×Cr-1.094×age-0.287×0.739 in female. Urinary 
excretions of α1-microglobulin and angiotensinogen were measured with ELISA kits; LZ 
Test Eiken α1-M (Eiken Chemical Co., Tokyo, Japan) and Human Total Angiotensinogen 
Assay Kit (Immuno-Biological Laboratories Co., Ltd., Fujioka, Gunma, Japan).  
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Statistical analysis 
All data are expressed as mean ± standard deviation (SD) values. Spearman 
correlation coefficients were used to evaluate whether urinary levels of angiotensinogen 
correlated with various parameters. To determine the variables independently 
associated with urinary levels of angiotensinogen in the patients with type 2 diabetes, 
multiple regression analysis was performed by including estimated glomerular filtration 
rate (eGFR), ACR and urinary α1-microglobulin / creatinine ratio as independent 
variables. Urinary levels of α1-microglobulin, angiotensinogen and various clinical 
parameters in RAS inhibitors (-) and RAS inhibitors (+) groups were compared by 
Mann-Whitney U. P values less than 0.05 were considered statistically significant. 
Statistical analysis was performed with IBM SPSS Statistics Base and IBM SPSS 
Regression (IBM, Armonk, NY). 
 
Results 
Urinary angiotensinogen well-correlated with urinary α1-microglobulin 
The type 2 diabetes patients (n=85) with various albuminuria stages, i.e. normo- (n=36), 
micro- (n=25) and macroalbuminuric (n=24) stages, were recruited into the study and 
they were classified into RAS inhibitors (-) and RAS inhibitors (+) groups (Table 1). At 
three albuminuria stages, the serum concentrations of total protein (70.4±4.3, 70.7±4.8, 
66.1±6.5 g/L; p=0.003), albumin (42.9±2.5, 41.2±3.2, 35.7±7.0 g/L; p=1.80x10-16), 
creatinine (66.4±13.3, 78.3±26.3, 144.2±70.3 μmol/L; p=4.86x10-10), urea nitrogen 
(5.5±1.5, 7.1±2.7, 10.0±3.8 μmol/L; p=5.92x10-8), uric acid (305.8±61.5, 352.8±96.2, 
396.2±68.0 μmol/L; p=9.68x10-5), HDL-C (1.49±0.41, 1.35±0.31, 1.23±0.39 mmol/L; 
p=0.031), and eGFR (74.5±16.3, 67.9±19.2, 42.4±19.0 mL/min; p=6.66x10-9) 
significantly changed demonstrated by Kruskal-Wallis test. Urinary proteins also 
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significantly increased with the progression of albuminuria stages; ACR (12.7±6.0, 
114.3±72.6, 1424±996 mg/gCr; p=1.81x10-16), urinary α1-microgloburin (4.24±4.03, 
6.30±5.12, 17.83±18.08 μg/gCr; p=8.84x10-9), and urinary angiotensinogen (6.8±11.6, 
8.5±9.9, 73.3±95.2 μg/gCr; p=2.88 x10-4). 
By simple regression analyses of these parameters, urinary angiotensinogen levels 
significantly and positively correlated with ACR (r=0.376, p=3.84x10-4) and urinary 
α1-microglobulin (r=0.734, p=1.32x10-15), while they significantly and negatively 
correlated with eGFR (r=-0.350, p=3.84x10-4) and HDL-C (r=-0.216, p=0.049) (Table 2, 
Figure 1). We next investigated the correlations of urinary angiotensinogen, ACR and 
urinary α1-microglobulin in various albuminuria stages. At all three albuminuria stages, 
urinary angiotensinogen levels did not correlate with ACR; however urinary 
angiotensinogen levels significantly and highly correlate with α1-microglobulin at 
normoalbumunuria stage (r=0.840, p=1.40x10-10)(Figure 2). By multiple regression 
analysis by including all parameters, eGFR, ACR and urinary α1-microglobulin, as 
independent variables, only urinary α1-microglobulin was a significant independent 
variable (Table 3, Model 1). Furthermore, in stepwise multiple regression analysis, only 
urinary α1-microglobulin was employed as independent variable (Table 3, Model 2).  
 
Urinary angiotensinogen and α1-microglobulin levels were not altered in RAS 
inhibitors (+) and (-) groups 
We next compared various clinical parameters in RAS inhibitors (+) and (-) groups. In 
RAS inhibitors (+), ACR was significantly higher compared with RAS inhibitors (-) group 
(368.2±863.8 v.s. 489.8±779.8 mg/gCr, p=0.006). In contrast, urinary α1-microglobulin 
and angiotensinogen did not show significantly differences between two groups (Figure 
3). In clinical practice, the type 2 diabetes patients with higher ACR seem to be 
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preferentially treated with ARB or ACEI. Since urinary α1-microglobulin and 
angiotensinogen levels were not significantly higher in RAS inhibitors (+) group, tubular 
damage and subsequent intrarenal RAS activation may be ameliorated by the 
administration of ARB or ACEI in RAS inhibitors (+) group. 
 
Discussion 
Proximal tubular angiotensinogen, collecting duct renin, and tubular angiotensin II 
type 1 (AT1) receptors are positively augmented by intrarenal angiotensin II (Ang II)4. 
The infusion of 125I-Ang II into pigs demonstrated that steady-state concentrations of 
125I-Ang II in cortical and medullary tissue were 4- and 2-fold higher than arterial plasma 
and the tissue concentrations of endogenous Ang II were 100- and 60- times higher 
than arterial plasma5. Thus, it suggested that most renal AT1 receptors are exposed to 
locally generated Ang II rather than Ang II from circulation. In rodent models, the urinary 
excretion of angiotensinogen in streptozotocin-induced diabetic mice at 3 days after the 
induction of diabetes was significantly higher (349.6 ± 89.1 μg/day) than control mice 
(15.9 ± 2.2 μg/day) and the authors demonstrated the up-regulation of angiotensinogen 
mRNA and protein expression in the mouse kidneys6. The data suggested that urinary 
excretion of angiotensinogen is a biomarker for the activation of RAS in the kidney 
under diabetic states. In human, plasma angiotensinogen reaches urine via glomerular 
filtration like albumin and normal urinary angiotensinogen levels in human are ~0.2 
pmol/mL versus ~1200 pmol/mL in plasma. Thus, the urinary angiotensinogen levels 
range from 0.01 to 0.1% of the plasma levels in human. In contrast, urinary 
angiotensinogen levels in rodents are much higher and range from 0.1 to 400 pmol/mL, 
implying that the urinary angiotensinogen levels in rodents sometimes higher than their 
plasma levels1. <100-fold higher urinary angiotensinogen levels in rodents suggested 
the concept, in which urinary angiotensinogen is exclusively plasma-derived in humans, 
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whereas it reflects angiotensinogen release from renal tissues, possibly proximal 
tubules, in rodents. Since albumin is produced in the liver and urinary albumin is entirely 
derived from plasma, the comparison of urinary albumin and angiotensinogen would 
demonstrate to what degree of urinary angiotensinogen is plasma-derived in human. In 
fact, several studies2, 7-9 demonstrated tight correlations between urinary albumin and 
angiotensinogen without exception.  
   In current investigation, we simultaneously measured ACR, urinary α1-microglobulin 
and urinary angiotensinogen levels in the patients with type 2 diabetes and various 
stages of diabetic nephropathy. Urinary angiotensinogen levels significantly and 
positively correlated with ACR (r=0.376, p=3.84x10-4) as previous reports and we also 
found further tight correlation with urinary α1-microglobulin (r=0.734, p=1.32x10-15). 
Tight correlation of urinary α1-microglobulin and angiotensinogen levels was also true 
both in microalbuminuria and macroalbuminruia stages; however, ACR did not show 
significant correlation with urinary angiotensinogen at normo-, micro- and 
macroalbuminuria stages. The high correlation between urinary α1-microglobulin and 
angiotensinogen levels at normoalbuminuric stage supported the concept that tubular 
damage promotes the intrarenal RAS activation and production of tubular 
angiotensinogen, since the normoalbuminuric patients would not be expected to have 
leakage of plasma angiotensinogen into urinary space.  
Urinary α1-microglobulin is filtered freely though glomerular capillaries and 
reabsorbed by the proximal tubules10. Thus, urinary α1-microglobulin is a marker for 
proximal tubule dysfunction and the increased levels of urinary α1-microglobulin has 
been reported in normoalbuminuric patients with type 1 diabetes11, 12 and type 2 
diabetes10, 13, 14. The assessment of proximal tubule dysfunction in the course of 
diabetes by urinary α1-microglobulin allows the early diagnosis of diabetic nephropathy 
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in prior to the appearance of microalbuminuria and also predicts the progression of 
diabetic nephropathy. Plasma angiotensinogen is filtered through glomerular capillaries 
and urinary angiotensinogen is mainly derived from plasma. Subsequently, urinary 
angiotensinogen is largely removed via endocytotic uptake in tubules in a 
megalin-dependent manner. Endocytotic angiotensinogen is subsequently degraded 
and the contents of angiotensinogen in the proximal convoluted tubules tightly 
correlated with plasma levels of angiotensinogen15. Thus, previous studies also support 
the idea that urinary excretion of angiotensinogen reflects not only abnormalities of 
glomerular filtration barrier but also proximal tubular functions. Actually it has been 
reported that urinary angiotensinogen levels increase before glomerular injuries in the 
patients16 as well as in rodents6.  
   Yamamoto et al. demonstrated that administration of losartan reduced urinary and 
plasma angiotensinogen levels in the patients with chronic kidney disease17. In 
hypertensive patients with a preserved kidney function, RAS blockers decreased the 
urinary angiotensinogen and the decrease was comparable to that in urinary albumin7. 
Furthermore, in IgA nephropathy, the treatment with valsartan also reduced urinary 
angiotensinogen18, 19. As various kidney diseases, RAS inhibitors suppressed urinary 
angiotensinogen levels with type 2 diabetes20. One can speculate that reduction of 
urinary angiotensinogen by RAS blockers is due to the amelioration of glomerular 
hyperfiltration and suppression of enhanced filtration of various proteins including 
angiotensinogen through glomerular capillaries. Although ACR was higher in RAS 
inhibitors (+) group, urinary α1-microglobulin and angiotensinogen did not show 
significant increase in RAS inhibitors (+) group. Thus, we speculate that RAS inhibitors 
may ameliorate the tubular injuries and intrarenal RAS activation which was reflected by 
no significant increase in urinary α1-microglobulin and angiotensinogen levels. 
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Conclusion 
  In summary, we demonstrated the significant and positive correlation of urinary 
angiotensinogen levels with ACR and urinary α1-microglobulin, and the negative 
correlation with eGFR. By multiple regression analysis by including all parameters, 
eGFR, ACR and urinary α1-microglobulin, as independent variables, only urinary 
α1-microglobulin was a significant independent variable. The current cross-sectional 
clinical study revealed that urinary angiotensinogen is a marker for the tubular injuries of 
early stage of diabetic nephropathy in the patients with type 2 diabetes. Since the 
current study was cross-sectional clinical investigation, the limitation was that it is still 
unknown the significance of urinary angiotensinogen for predicting long-term course of 
diabetic nephropathy. In the future prospective study, the significance of urinary 
angiotensinogen in predicting the progression of diabetic nephropathy needs to be 
demonstrated. 
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Figure legends 
 
Figure 1 Simple correlation of urinary excretion of angiotensinogen with urinary albumin 
creatinine ratio (ACR), estimated glomerular filtration ratio (eGFR), urinary 
α1-microglobulin and high density lipoprotein cholecterol (HDL-C) in the patients with 
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diabetic nephropathy (n=85). Spearman correlation coefficients are used. 
 
Figure 2 Simple correlation of urinary excretion of angiotensinogen with urinary albumin 
creatinine ratio (ACR) and urinary α1-microglobulin in the type 2 diabetes patients 
(n=85) with normo- (n=36), micro- (n=25) and macroalbuminuric (n=24) stages. 
Spearman correlation coefficients are used. 
 
Figure 3 Urinary albumin creatinine ratio (ACR), estimated glomerular filtration ratio 
(eGFR), urinary excretion of α1-microglobulin, and urinary excretion of angiotensinogen 
in the patients with various stages of diabetic nephropathy (n=85). Urinary levels of 
albumin, α1-microglobulin, angiotensinogen and eGFR in RAS inhibitors (-) and RAS 
inhibitors (+) groups are compared by Mann-Whitney U. 
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Table 1 Comparison of various parameters in the type 2 diabetes patients (n=85) with 
normo- (n=36), micro- (n=25) and macroalbuminuric (n=24) stages. The patients are 
classified whether they are treated with or without angiotensin receptor blockers or 
angiotensin converting enzyme inhibitors. 
 
RAS 
inhibitors (-)
RAS 
inhibitors (+)
Total 
Mann-Whitney 
U 
Number (male/female) 34 (16 / 18) 51 (33 / 18) 85 (49 / 36)  
Age (years) 63.1±11.7 62.5±11.1 62.9±11.3 0.492 
BMI (kg/m2) 24.5±4.4 25.1±4.7 24.9±4.6 0.618 
SBP (mmHg) 122.9±13.4 128.3±19.2 126.2±17.3 0.216 
DBP (mmHg) 71.2±10.9 72.8±11.2 72.2±11.1 0.339 
HbA1c (%) 7.27±0.68 7.33±0.98 7.31±0.87 0.974 
Total protein (g/L) 70.1±5.8 68.7±5.1 69.3±5.4 0.339 
Albumin (g/L) 41.4±5.8 39.6±5.0 40.4±5.3 0.032* 
Cr (μmol/L) 81.4±53.9 98.8±50.6 91.9±52.3 0.028* 
UN (μmol/L) 7.0±3.4 7.4±3.2 7.3±3.3 0.418 
Uric acid (μmol/L) 321.3±66.8 360.3±89.8 344.6±83.1 0.034* 
T-Cho (mmol/L) 5.32±1.01 4.77±0.88 4.99±0.97 0.011* 
TG (mmol/L) 1.76±1.07 1.84±1.37 1.81±1.26 0.904 
HDL-C (mmol/L) 1.51±0.45 1.29±0.31 1.38±0.39 0.041* 
LDL-C (mmol/L) 3.03±0.84 2.62±0.74 2.79±0.80 0.024 
eGFR (mL/min) 68.5±20.7 60.2±23.0 63.5±22.4 0.052 
ACR (mg/gCr) 368.2±863.8 489.8±779.8 441.2±812 0.006** 
α1-microglobulin 
(μg/gCr) 7.26±13.2 9.63±10.6 8.68±11.74 0.306 
Angiotensinogen 
(μg/gCr) 13.3±27.5 34.6±71.5 26.1±58.8 0.374 
RAS inhibitors (+); The patients treated with angiotensin II receptor blockers or 
angiotensin converting enzyme inhibitors; BMI, body mass index; SBP, Systolic Blood 
Pressure; DPB, Diastolic Blood Pressure; Cr, serum creatinine; UN, serum urea 
nitrogen; T-Cho, Total cholesterol; TG, Triglyceride; HDL-C, HDL cholesterol; LDL-C, 
LDL cholesterol; eGFR, estimated glomerular filtration ratio; ACR, albumin / creatinine 
ratio; *, p < 0.05; **, p < 0.01. 
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Table 2 Simple correlation of urinary angiotensinogen with various clinical parameters in 
the patients with type 2 diabetes (n=85) 
 Angiotensinogen (μg/gCr) 
Age (years) R=-0.040, p=0.713 
BMI (kg/m2) R=-0.086, p=0.431 
SBP (mmHg) R=-0.033, p=0.764 
DBP (mmHg) R=-0.173, p=0.113 
HbA1c (%) R=-0.039, p=0.726 
Total protein (g/L) R=-0.107, p=0.338 
Albumin (g/L) R=-0.165, p=0.136 
Cr (μmol/L) R=0.243, p=0.025* 
UN (μmol/L) R=0.362, p=0.001** 
Uric acid (μmol/L) R=0.081, p=0.462 
T-Cho (mmol/L) R=-0.109, p=0.325 
TG (mmol/L) R=0.012, p=0.911 
HDL-C (mmol/L) R=-0.216, p=0.049* 
LDL-C (mmol/L) R=-0.051, p=0.646 
eGFR (mL/min) R=-0.350, p=1.02x10-3** 
ACR (mg/gCr) R=0.376, p=3.84x10-4** 
α1-microglobulin (μg/gCr) R=0.734, p=1.32x10-15** 
BMI, body mass index; SBP, Systolic Blood Pressure; DPB, Diastolic Blood Pressure; 
Cr, serum creatinine; UN, serum urea nitrogen; T-Cho, Total cholesterol; TG, 
Triglyceride; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; eGFR, estimated 
glomerular filtration ratio; ACR, albumin / creatinine ratio; *, p < 0.05; **, p < 0.01. 
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Table 3 Multiple linear regression analysis using urinary angiotensinogen as dependent 
variable in the patients with type 2 diabetes (n=85). 
Dependent 
variable 
Independent 
variable 
Unstandardized 
coefficient 
Standardized 
coefficient 
t value P value 
Adjusted 
R2 
B 
Standard 
Error 
Beta 
Model 1 
Urinary 
angiotensinogen 
(μg/gCr) 
ACR (mg/gCr) 
eGFR (mL/min) 
Urinary 
α1-microglobulin 
(μg/gCr) 
-0.001 
0.022 
3.647 
0.007 
0.246 
0.498 
0.014 
0.009 
0.728 
0.142 
0.091 
7.324 
0.888 
0.928 
1.58x10-10 0.519 
Model 2 
Urinary 
angiotensinogen 
(μg/gCr) 
Urinary α1-micro
globulin (μg/gCr) 
3.668 0.374 0.732 9.800 1.64x10-15 
0.531 
Estimated glomerular filtration rate (eGFR) (mL/min), albumin / creatinine ratio (ACR) 
(mg/gCr) and α1-microglobulin (μg/gCr) are used as independent variables in multiple 
linear regression analysis. In Model 1, all parameters are included and stepwise multiple 
linear regression analysis is performed in Model 2.  *, p < 0.05; **, p < 0.01. 
 
 
a b
c d
R=0.376, p=3.84x10-4 R=-0.350, p=1.02x10-3
R=0.734, p=1.32x10-15 R=-0.216, p=0.049
Figure 1
a b
R=0.840, p=1.40x10-10 R=-0.053, p=0.759
R=0.365, p=0.072 R=-0.050, p=0.812
R=0.775, p=8.80x10-6 R=0.010, p=0.961
Normoalbuminuria Normoalbuminuria
c dMicroalbuminuria Microalbuminuria
e fMacroalbuminuria Macroalbuminuria
Figure 2
p=0.006 p=0.052
p=0.306 p=0.374
a b
c d
Figure 3
(-)            (+) (-)            (+)
(-)            (+) (-)            (+)
